Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07333716
PHASE2

Desloratadine in Patients With Ulcerative Colitis

Sponsor: Tanta University

View on ClinicalTrials.gov

Summary

The purpose of this study is to investigate safety and therapeutic efficacy of antihistamine (desloratadine) on inflammation and disease activity when administered as adjuvant therapies with the traditional therapy 5-aminosalisylic acid (mesalamine) in patients with mild to moderate ulcerative colitis.

Official title: Efficacy and Safety of Desloratadine as Adjuvant Therapy in Patients With Ulcerative Colitis

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

44

Start Date

2026-01-26

Completion Date

2027-03

Last Updated

2026-01-29

Healthy Volunteers

No

Interventions

DRUG

Desloratadine

mesalamine 1000 mg three times daily plus desloratadine 5 mg once daily for 3 months.

DRUG

mesalamine

mesalamine 1000 mg three times daily for 3 months

Locations (1)

Menofia university Hospitals

Shibīn al Kawm, Menofia, Egypt